Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.The study of cancer genomics has dramatically evolved over the last 30 years.
The era of genomic medicine in oncology started in the 1980s when the relationship between karyotype abnormalities and diseases were identified, thereby allowing better patient stratification. Soon this approach became common in leukemia as well as in solid tumors treatment. The next step was to define the role of oncogenes and proto-oncogenes in tumor formation and progression.
Kay-Oliver Kliche, MD , Medical Director of Hematology and Oncology, Medical Affairs PRA Health Sciences shares his thoughts on the brief history of oncology genomics research and discusses its current achievements as well as the future direction of cancer genomics.
Key points that were highlighted include
> Regulatory concerns cancer genomics clinical research
> Assay determination and trial design framework limitations
> Incorporation of epigenetic changes in trials strategies etc
If you are in cancer genomics research and like to find out more about how you can further your research or discuss collaboration opportunities, network with PRA at the BioPharma Asia Convention 2015 exhibition (24 – 25 March 2015). They are located at B02.
To learn about Asia’s most important biopharma industry gathering and to have an idea of who else is attending this year’s event, log to the BioPharma Asia Convention 2015 website for more details.